- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06875700
Beliefs, Attitudes, and Interest in Genetic Testing in Sarcoma Patients (SPORE)
Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients is not yet established. This study will assess beliefs about the heritability of leiomyosarcoma (LMS) and other cancers, and attitudes toward germline testing among LMS patients.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is a descriptive study to explore attitudes toward genomics and interest in receiving personal genetic information among patients with leiomyosarcoma (LMS). The study aims to:
- Assess LMS patients' beliefs and attitudes about the heritability of LMS.
- Assess LMS patients' interest in genetic testing and their preferences for receiving information about genetic testing.
Prior studies of cancer patients have found strong interest in germline genetic testing to inform personal and familial cancer risk. However, germline genetic testing is not widely recommended for patients diagnosed with LMS, and little is known about patients' beliefs about the heritability of LMS or their interest in genetic testing. This study will use a survey to assess beliefs about the heritability of LMS, interest in genetic testing, and preferences for receiving information about genetic testing.
Participants will be identified by querying the Enterprise Data Warehouse (EDW) and the Huntsman Tumor Registry, recruiting in clinics at the Huntsman Cancer Institute, receiving referrals from providers outside the Huntsman Cancer Institute, and through LMS patient support and advocacy organizations.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Gregg Wood
- Telefonnummer: 801-646-4215
- E-post: gregg.wood@hci.utah.edu
Studieorter
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84112
- Rekrytering
- Huntsman Cancer Institute at the University of Utah
-
Kontakt:
- Wendy K Kohlmann, MS
- Telefonnummer: 801-587-5556
- E-post: wendy.kohlmann@hci.utah.edu
-
Huvudutredare:
- Wendy K Kohlmann, MS
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
The study population will be Patients with a confirmed or self reported diagnosis of LMS
Beskrivning
Inclusion
- Living
- Able to speak and read English or Spanish
- Mentally competent
- Age 18 or older
Exclusion
- <18 years
- Unable to read or write
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Patients with leiomyosarcoma
Electronic questionnaire assessing beliefs about the heritability of LMS and interest in genetic testing |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Beliefs about the heritability of Leiomyosarcoma
Tidsram: up to 1 day from study enrollment
|
This outcome will describe LMS patients' beliefs about the heritability of LMS as well as other cancers, diseases, and physical traits. A five point Likert scale is used to classify conditions from totally inherited to totally environmental. |
up to 1 day from study enrollment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Interest in germline genetic testing
Tidsram: up to 1 day from study enrollment
|
This outcome will report interest in genetic testing for cancer predisposition for themselves as well as for other people such as family members, children, and the general public. Likert scales will be used to assess general interest in genetics and genetic testing in general. Interest in genetic testing will also be assessed with questions about when in the lifespan testing should be offered and for which types of conditions. |
up to 1 day from study enrollment
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Preferences for receiving information about genetic testing.
Tidsram: up to 1 day from study enrollment
|
This outcome will report the count of participants who self reported sources for genetic testing information as helpful. Participants will rank questions about sources of information from "1 Not helpful at all" to "6 Extremely helpful" on their baseline questionnaire. Participants who reported >5 on this scale are considered to have found the source for genetic testing information as helpful. This outcome will assess information presented in tables and graphs and information presented numerically . |
up to 1 day from study enrollment
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Wendy Kohlmann, MS, Huntsman Cancer Institute
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 165523
- 1P50CA272170-01 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Deidentified IDP will be shared with the University of Michigan Rogel Cancer Center for data analysis.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .